Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Liver Cirrhosis

  Free Subscription


Articles published in Gut

Retrieve available abstracts of 75 articles:
HTML format



Single Articles


    March 2021
  1. JACKSON K, Davidson R, Aujayeb A
    Hepatic hydrothorax in the management of cirrhosis.
    Gut. 2021 Mar 31. pii: gutjnl-2021-324698. doi: 10.1136/gutjnl-2021-324698.
    PubMed    


    January 2021
  2. PETROFF D, Batz O, Jedrysiak K, Kramer J, et al
    Fibrosis-4 (FIB-4) score at the primary care level: an analysis of over 160 000 blood samples.
    Gut. 2021;70:219-221.
    PubMed    


    October 2020
  3. PRAKTIKNJO M, Schierwagen R, Monteiro S, Ortiz C, et al
    Hepatic inflammasome activation as origin of Interleukin-1alpha and Interleukin-1beta in liver cirrhosis.
    Gut. 2020 Oct 21. pii: gutjnl-2020-322621. doi: 10.1136/gutjnl-2020-322621.
    PubMed    


  4. AITHAL GP, Palaniyappan N, China L, Harmala S, et al
    Guidelines on the management of ascites in cirrhosis.
    Gut. 2020 Oct 16. pii: gutjnl-2020-321790. doi: 10.1136/gutjnl-2020-321790.
    PubMed     Abstract available


  5. TRANAH TH, Edwards LA, Schnabl B, Shawcross DL, et al
    Targeting the gut-liver-immune axis to treat cirrhosis.
    Gut. 2020 Oct 15. pii: gutjnl-2020-320786. doi: 10.1136/gutjnl-2020-320786.
    PubMed     Abstract available


  6. IAVARONE M, D'Ambrosio R, Lampertico P
    Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19.
    Gut. 2020 Oct 7. pii: gutjnl-2020-322929. doi: 10.1136/gutjnl-2020-322929.
    PubMed    


    September 2020
  7. BAJAJ JS, Sikaroodi M, Shamsaddini A, Henseler Z, et al
    Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
    Gut. 2020 Sep 30. pii: gutjnl-2020-322470. doi: 10.1136/gutjnl-2020-322470.
    PubMed     Abstract available


    August 2020
  8. SHARMA S, Elhence A, Vaishnav M, Kumar R, et al
    COVID-19 in patients with cirrhosis: understanding adverse impact.
    Gut. 2020 Aug 21. pii: gutjnl-2020-322561. doi: 10.1136/gutjnl-2020-322561.
    PubMed    


    July 2020
  9. BAJAJ JS, Garcia-Tsao G, Biggins S, Kamath PS, et al
    Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort.
    Gut. 2020 Jul 13. pii: gutjnl-2020-322118. doi: 10.1136/gutjnl-2020-322118.
    PubMed     Abstract available


  10. GEIER A, Boursier J
    Non-invasive diagnosis of patients with 'at-risk' NAFLD : only fibrosis counts?
    Gut. 2020;69:1164-1165.
    PubMed    


    June 2020
  11. STENGEL S, Steube A, Kose-Vogel N, Kirchberger-Tolstik T, et al
    Primed circulating monocytes are a source of IL-1beta in patients with cirrhosis and ascites.
    Gut. 2020 Jun 22. pii: gutjnl-2020-321597. doi: 10.1136/gutjnl-2020-321597.
    PubMed    


  12. BREITKOPF-HEINLEIN K, Syn WK
    Harnessing liver progenitors in the treatment of liver fibrosis: a step in the right direction?
    Gut. 2020;69:975-976.
    PubMed    


  13. DAI Z, Song G, Balakrishnan A, Yang T, et al
    Growth differentiation factor 11 attenuates liver fibrosis via expansion of liver progenitor cells.
    Gut. 2020;69:1104-1115.
    PubMed     Abstract available


  14. WANG Y, Wong GL, He FP, Sun J, et al
    Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Gut. 2020;69:1116-1126.
    PubMed     Abstract available


    May 2020
  15. QI X, Liu Y, Wang J, Fallowfield J, et al
    Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study.
    Gut. 2020 May 20. pii: gutjnl-2020-321666. doi: 10.1136/gutjnl-2020-321666.
    PubMed    


    April 2020
  16. MONTEIRO S, Grandt J, Uschner FE, Kimer N, et al
    Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation.
    Gut. 2020 Apr 2. pii: gutjnl-2019-320170. doi: 10.1136/gutjnl-2019-320170.
    PubMed     Abstract available


    March 2020
  17. HUTCHINSON SJ, Valerio H, McDonald SA, Yeung A, et al
    Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Gut. 2020 Mar 26. pii: gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007.
    PubMed     Abstract available


  18. SCHATTENBERG JM
    Prevention of endpoints in primary biliary cholangitis with ursodeoxycholic acid: quantifying the benefit.
    Gut. 2020 Mar 23. pii: gutjnl-2019-320355. doi: 10.1136/gutjnl-2019-320355.
    PubMed    


  19. BOSCH J, Gracia-Sancho J, Abraldes JG
    Cirrhosis as new indication for statins.
    Gut. 2020 Mar 5. pii: gutjnl-2019-318237. doi: 10.1136/gutjnl-2019-318237.
    PubMed     Abstract available


    February 2020
  20. BERNARDI M, Angeli P, Claria J, Moreau R, et al
    Albumin in decompensated cirrhosis: new concepts and perspectives.
    Gut. 2020 Feb 26. pii: gutjnl-2019-318843. doi: 10.1136/gutjnl-2019-318843.
    PubMed     Abstract available


  21. LOOMBA R, Adams LA
    Advances in non-invasive assessment of hepatic fibrosis.
    Gut. 2020 Feb 17. pii: gutjnl-2018-317593. doi: 10.1136/gutjnl-2018-317593.
    PubMed     Abstract available


    January 2020
  22. DROPMANN A, Dooley S, Dewidar B, Hammad S, et al
    TGF-beta2 silencing to target biliary-derived liver diseases.
    Gut. 2020 Jan 28. pii: gutjnl-2019-319091. doi: 10.1136/gutjnl-2019-319091.
    PubMed     Abstract available


    December 2019
  23. HARMS MH, de Veer RC, Lammers WJ, Corpechot C, et al
    Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis.
    Gut. 2019 Dec 16. pii: gutjnl-2019-319057. doi: 10.1136/gutjnl-2019-319057.
    PubMed     Abstract available


    November 2019
  24. JOHN M, Kim KJ, Bae SDW, Qiao L, et al
    Role of BMP-9 in human liver disease.
    Gut. 2019;68:2097-2100.
    PubMed    


  25. WONG VW, Irles M, Wong GL, Shili S, et al
    Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease.
    Gut. 2019;68:2057-2064.
    PubMed     Abstract available


    October 2019
  26. CHEN Y, Lin XY
    Are the 5-hydroxymethylcytosine-based wd-scores really superior over alpha-fetoprotein for the early diagnosis of hepatocellular carcinoma?
    Gut. 2019 Oct 25. pii: gutjnl-2019-319853. doi: 10.1136/gutjnl-2019-319853.
    PubMed    


  27. CAUSSY C, Ajmera VH, Puri P, Hsu CL, et al
    Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.
    Gut. 2019;68:1884-1892.
    PubMed     Abstract available


    September 2019
  28. MARTI-RODRIGO A, Alegre F, Moragrega AB, Garcia-Garcia F, et al
    Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
    Gut. 2019 Sep 17. pii: gutjnl-2019-318372. doi: 10.1136/gutjnl-2019-318372.
    PubMed     Abstract available


    August 2019
  29. SAROBE P, Corrales F
    Getting insights into hepatocellular carcinoma tumour heterogeneity by multiomics dissection.
    Gut. 2019 Aug 2. pii: gutjnl-2019-319410. doi: 10.1136/gutjnl-2019-319410.
    PubMed    


    July 2019
  30. QUECK A, Carnevale R, Uschner FE, Schierwagen R, et al
    Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS.
    Gut. 2019 Jul 3. pii: gutjnl-2019-319044. doi: 10.1136/gutjnl-2019-319044.
    PubMed    


    June 2019
  31. TAO L, Ma W, Wu L, Xu M, et al
    Glial cell line-derived neurotrophic factor (GDNF) mediates hepatic stellate cell activation via ALK5/Smad signalling.
    Gut. 2019 Jun 6. pii: gutjnl-2018-317872. doi: 10.1136/gutjnl-2018-317872.
    PubMed     Abstract available


    May 2019
  32. LIU M, Zhou J, Liu X, Feng Y, et al
    Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Gut. 2019 May 10. pii: gutjnl-2018-317257. doi: 10.1136/gutjnl-2018-317257.
    PubMed     Abstract available


    April 2019
  33. SINGHI AD, Nikiforova MN, Chennat J, Papachristou GI, et al
    Integrating next-generation sequencing to endoscopic retrograde cholangiopancreatography (ERCP)-obtained biliary specimens improves the detection and management of patients with malignant bile duct strictures.
    Gut. 2019 Apr 10. pii: gutjnl-2018-317817. doi: 10.1136/gutjnl-2018-317817.
    PubMed     Abstract available


    January 2019
  34. YUAN L, Jiang J, Liu X, Zhang Y, et al
    HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation.
    Gut. 2019 Jan 30. pii: gutjnl-2018-316091. doi: 10.1136/gutjnl-2018-316091.
    PubMed     Abstract available


    November 2018
  35. LV Y, Zuo L, Zhu X, Zhao J, et al
    Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.
    Gut. 2018 Nov 10. pii: gutjnl-2018-317057. doi: 10.1136/gutjnl-2018-317057.
    PubMed     Abstract available


    October 2018
  36. LU XJ, Li XH, Yuan ZX, Sun HY, et al
    Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: a multicentre validation in patients with HBV infection.
    Gut. 2018;67:1903-1904.
    PubMed    


    September 2018
  37. KREMER AE, Le Cleac'h A, Lemoinne S, Wolf K, et al
    Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis.
    Gut. 2018 Sep 18. pii: gutjnl-2018-317426. doi: 10.1136/gutjnl-2018-317426.
    PubMed    


    August 2018
  38. STRNAD P, Buch S, Hamesch K, Fischer J, et al
    Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis.
    Gut. 2018 Aug 1. pii: gutjnl-2018-316228. doi: 10.1136/gutjnl-2018-316228.
    PubMed     Abstract available


    July 2018
  39. REN Z, Li A, Jiang J, Zhou L, et al
    Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma.
    Gut. 2018 Jul 25. pii: gutjnl-2017-315084. doi: 10.1136/gutjnl-2017-315084.
    PubMed     Abstract available


    May 2018
  40. WANG K, Lu X, Zhou H, Gao Y, et al
    Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study.
    Gut. 2018 May 5. pii: gutjnl-2018-316204. doi: 10.1136/gutjnl-2018-316204.
    PubMed     Abstract available


    April 2018
  41. SHIHA G, Esmat G, Hassany M, Soliman R, et al
    Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
    Gut. 2018 Apr 17. pii: gutjnl-2017-315906. doi: 10.1136/gutjnl-2017-315906.
    PubMed     Abstract available


    March 2018
  42. HIRSCHFIELD GM, Dyson JK, Alexander GJM, Chapman MH, et al
    The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines.
    Gut. 2018 Mar 28. pii: gutjnl-2017-315259. doi: 10.1136/gutjnl-2017-315259.
    PubMed     Abstract available


  43. LUETKENS JA, Klein S, Traeber F, Schmeel FC, et al
    Quantitative liver MRI including extracellular volume fraction for non-invasive quantification of liver fibrosis: a prospective proof-of-concept study.
    Gut. 2018;67:593-594.
    PubMed    


    February 2018
  44. RENZULLI M, Biselli M, Brocchi S, Granito A, et al
    New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
    Gut. 2018 Feb 3. pii: gutjnl-2017-315384. doi: 10.1136/gutjnl-2017-315384.
    PubMed     Abstract available


  45. MURATA K, Asano M, Matsumoto A, Sugiyama M, et al
    Induction of IFN-lambda3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.
    Gut. 2018;67:362-371.
    PubMed     Abstract available


    January 2018
  46. PERUGORRIA MJ, Esparza-Baquer A, Oakley F, Labiano I, et al
    Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage.
    Gut. 2018 Jan 27. pii: gutjnl-2017-314107. doi: 10.1136/gutjnl-2017-314107.
    PubMed     Abstract available


  47. YIGIT B, Boyle M, Ozler O, Erden N, et al
    Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis.
    Gut. 2018 Jan 20. pii: gutjnl-2017-315668. doi: 10.1136/gutjnl-2017-315668.
    PubMed    


    September 2017
  48. LV Y, Qi X, He C, Wang Z, et al
    Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
    Gut. 2017 Sep 28. pii: gutjnl-2017-314634. doi: 10.1136/gutjnl-2017-314634.
    PubMed     Abstract available


  49. WU T, Li J, Shao L, Xin J, et al
    Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
    Gut. 2017 Sep 19. pii: gutjnl-2017-314641. doi: 10.1136/gutjnl-2017-314641.
    PubMed     Abstract available



  50. Erratum: The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Gut. 2017;66:1730.
    PubMed    


  51. MAGDALENO F, Trebicka J
    Selective LOXL2 inhibition: potent antifibrotic effects in ongoing fibrosis and fibrosis regression.
    Gut. 2017;66:1540-1541.
    PubMed    


    August 2017
  52. PIANO S, Bartoletti M, Tonon M, Baldassarre M, et al
    Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections.
    Gut. 2017 Aug 31. pii: gutjnl-2017-314324. doi: 10.1136/gutjnl-2017-314324.
    PubMed     Abstract available


  53. ZHANG W, Sun M, Chen G, An Y, et al
    Reassessment of gamma-glutamyl transpeptidase to platelet ratio (GPR): a large-sample, dynamic study based on liver biopsy in a Chinese population with chronic hepatitis B virus (HBV) infection.
    Gut. 2017 Aug 16. pii: gutjnl-2017-313896. doi: 10.1136/gutjnl-2017-313896.
    PubMed    


    July 2017
  54. XIANG DM, Sun W, Ning BF, Zhou TF, et al
    The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis.
    Gut. 2017 Jul 28. pii: gutjnl-2016-313392. doi: 10.1136/gutjnl-2016-313392.
    PubMed     Abstract available


  55. ALBANO E, Stickel F
    Targeting toll-like receptor 7/8 improves host anti-infective response in alcoholic cirrhosis.
    Gut. 2017 Jul 7. pii: gutjnl-2017-314437. doi: 10.1136/gutjnl-2017-314437.
    PubMed    


  56. HARDY T, Zeybel M, Day CP, Dipper C, et al
    Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
    Gut. 2017;66:1321-1328.
    PubMed     Abstract available


  57. MANDORFER M, Peck-Radosavljevic M, Reiberger T
    Prevention of progression from small to large varices: are we there yet? An updated meta-analysis.
    Gut. 2017;66:1347-1349.
    PubMed    


    June 2017
  58. ROLAS L, Boussif A, Weiss E, Letteron P, et al
    NADPH oxidase depletion in neutrophils from patients with cirrhosis and restoration via toll-like receptor 7/8 activation.
    Gut. 2017 Jun 10. pii: gutjnl-2016-313443. doi: 10.1136/gutjnl-2016-313443.
    PubMed     Abstract available


  59. BAJAJ JS, Liu EJ, Kheradman R, Fagan A, et al
    Fungal dysbiosis in cirrhosis.
    Gut. 2017 Jun 3. pii: gutjnl-2016-313170. doi: 10.1136/gutjnl-2016-313170.
    PubMed     Abstract available


  60. ARRIAZU E, Ge X, Leung TM, Magdaleno F, et al
    Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.
    Gut. 2017;66:1123-1137.
    PubMed     Abstract available


  61. SCHIAVON LL, Narciso-Schiavon JL, Ferraz MLG, Silva AEB, et al
    The gamma-glutamyl transpeptidase to platelet ratio (GPR) in HBV patients: just adding up?
    Gut. 2017;66:1169-1170.
    PubMed    


    May 2017
  62. BREITKOPF-HEINLEIN K, Meyer C, Konig C, Gaitantzi H, et al
    BMP-9 interferes with liver regeneration and promotes liver fibrosis.
    Gut. 2017;66:939-954.
    PubMed     Abstract available


    February 2017
  63. ARNOLD F, Patch D, Yu D, Westbrook RH, et al
    When banding fails; investigation hails.
    Gut. 2017;66:322.
    PubMed    


    January 2017
  64. MENARD A, Aherfi S, Mokhtari S, Dhiver C, et al
    Toward chronic hepatitis C eradication in HIV-positive patients, including those cirrhotic and infected with genotype 3 viruses.
    Gut. 2017 Jan 10. pii: gutjnl-2016-313431. doi: 10.1136/gutjnl-2016-313431.
    PubMed    


  65. IKENAGA N, Peng ZW, Vaid KA, Liu SB, et al
    Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal.
    Gut. 2017 Jan 10. pii: gutjnl-2016-312473. doi: 10.1136/gutjnl-2016-312473.
    PubMed     Abstract available


  66. AUGUSTIN S, Pons M, Genesca J
    Ruling in and ruling out with elastography in compensated advanced chronic liver disease.
    Gut. 2017;66:197-198.
    PubMed    


  67. LEMOINE M, Thursz M, Mallet V, Shimakawa Y, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio (GPR) using transient elastography as a reference.
    Gut. 2017;66:195-196.
    PubMed    


    September 2016
  68. KUTTKAT N, Mohs A, Ohl K, Hooiveld G, et al
    Hepatic overexpression of cAMP-responsive element modulator alpha induces a regulatory T-cell response in a murine model of chronic liver disease.
    Gut. 2016 Sep 29. pii: gutjnl-2015-311119. doi: 10.1136/gutjnl-2015-311119.
    PubMed     Abstract available


  69. DAHEIM M, Lang S, Goeser T, Steffen HM, et al
    Real-world risk score for hepatocellular carcinoma risk prediction in CHBV: a validation outside of Asia.
    Gut. 2016 Sep 26. pii: gutjnl-2016-312993. doi: 10.1136/gutjnl-2016-312993.
    PubMed    


    July 2016
  70. WELZEL TM, Nelson DR, Morelli G, Di Bisceglie A, et al
    Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Gut. 2016 Jul 13. pii: gutjnl-2016-311609. doi: 10.1136/gutjnl-2016-311609.
    PubMed     Abstract available


  71. SHIMAKAWA Y, Bonnard P, El Kassas M, Abdel-Hamid M, et al
    Diagnostic accuracy of the gamma-glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4.
    Gut. 2016 Jul 7. pii: gutjnl-2016-312326. doi: 10.1136/gutjnl-2016-312326.
    PubMed    


    June 2016
  72. STICKEL F, Dubuquoy L
    MicroRNA in alcoholic hepatitis: implications for pathophysiology and treatment.
    Gut. 2016 Jun 1. pii: gutjnl-2016-312101. doi: 10.1136/gutjnl-2016-312101.
    PubMed    


    April 2016
  73. JANSEN C, Bogs C, Krag A, Francque S, et al
    Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease.
    Gut. 2016 Apr 27. pii: gutjnl-2016-311955. doi: 10.1136/gutjnl-2016-311955.
    PubMed    


    February 2016
  74. EHLKEN H, Wroblewski R, Corpechot C, Arrive L, et al
    Spleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis.
    Gut. 2016 Feb 26. pii: gutjnl-2016-311452. doi: 10.1136/gutjnl-2016-311452.
    PubMed    


  75. JANSEN C, Bogs C, Verlinden W, Thiele M, et al
    Algorithm to rule out clinically significant portal hypertension combining Shear-wave elastography of liver and spleen: a prospective multicentre study.
    Gut. 2016 Feb 19. pii: gutjnl-2016-311536. doi: 10.1136/gutjnl-2016-311536.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: